[Featured Stock] Jinwon Life Sciences Rises on News of Applying for Phase 2 Clinical Trial of Oral COVID-19 Treatment
[Asia Economy Reporter Jang Hyowon] Jinwon Life Sciences is showing strong performance following news that it has submitted an application for a Phase 2 clinical trial of its oral COVID-19 treatment to the Ministry of Food and Drug Safety (MFDS).
As of 11:30 AM on the 1st, Jinwon Life Sciences is trading at 18,000 KRW, up 8.43% compared to the previous day.
On this day, Jinwon Life Sciences announced that it has submitted a clinical trial approval application to the MFDS for the Phase 2 clinical trial of GLS-1027, an oral COVID-19 treatment.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- With Pop Stars Flocking to Korea, $1.7 Billion Concert Market Emerges... Korea Becomes a ‘Must-Visit Hub’ for Asia Tours
- "Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
The clinical trial application submitted by Jinwon Life Sciences is titled "A dose-escalation, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety, tolerability, and efficacy of orally administered GLS-1027 for the prevention of severe pneumonia caused by coronavirus-19 infection."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
